• Aastrom Biosciences Inc., of Ann Arbor, Mich., named LaVonne Lang head of regulatory affairs.
• Albany Molecular Research Inc., of Albany, N.Y., appointed Tom McGrath director, quality for aseptic services at its Burlington, Mass., site.
• Alkermes plc, of Dublin, Ireland, appointed Mark Stejbach chief commercial officer.
• Alnylam Pharmaceuticals Inc., of Cambridge, Mass., named Cynthia Clayton vice president of investor relations and corporate communications.
• Amarillo Biosciences Inc., of Amarillo, Texas, appointed Stephen Chen CEO and chairman.
• AnaptysBio Inc., of San Diego, added David L. Lacey and Michael Gallatin to its therapeutic advisory board.
• Arbor Pharmaceuticals Inc., of Atlanta, appointed Leslie Zacks general counsel and chief compliance officer.
• C3 Jian Inc., of Inglewood, Calif., named Brian Varnum vice president of product development.
• Cellerant Therapeutics Inc., of San Carlos, Calif., appointed Lowell Sears to its board.
• CombiMatrix Corp., of Irvine, Calif., appointed Richard Ding and Joseph Limber to its board.
• Complete Genomics Inc., formed a genomic medicine advisory board and appointed Jonathan S. Berg, Charis Eng, Brynn Levy, Elaine Lyon, Federico A. Monzon, DesiRae Muirhead, Stirling M. Puck, Heidi Rehm as board members.
• Coronado Biosciences Inc., of Burlington, Mass., named Lucy Lu executive vice president and chief financial officer.
• CytomX Therapeutics Inc., of South San Francisco, appointed Hoyoung Huh chairman of its board.
• Dendreon Corp., of Seattle, appointed Joe DePinto executive vice president, global commercial operations; Robert S. Poulton, executive vice president, technical operations; and Christine Mikail, executive vice president, corporate development, general counsel and secretary.
• Dyax Corp., of Burlington, Mass., appointed Burt Adelman chief medical officer.
• Emisphere Technologies Inc., of Cedar Knolls, N.J., appointed Tim McInerney and Jacob Plotsker to its board.
• Galectin Therapeutics Inc., of Newton, Mass., named Thomas McGauley acting chief financial officer.
• Galena Biopharma, of Lake Oswego, Ore., added David Scheinberg to its scientific advisory board.
• Gentium Spa, of Villa Guardia, Italy, named Carin Heringa senior vice president and scientific director.
• Ico Therapeutics Inc., of Vancouver, British Columbia, added Douglas Janzen to its board.
• Idenix Pharmaceuticals Inc., of Cambridge, Mass., named Thomas Hodgson as chairman and Michael Wyzga as board member and chairman of the audit committee.
• Immunomedics Inc., of Morris Plains, N.J., added Marcella LoCastro to its board.
• Infinty Pharmaceuticals Inc., of Cambridge, Mass., appointed Gwen Fyfe and Norman Selby to its board.
• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., named Anthony Ford-Hutchinson to its scientific advisory board.
• Isconova AB, of Uppsala, Sweden, named Sven Andreasson CEO, and Russell G. Greig was appointed chairman of the board.
• Islet Sciences Inc., of New York, part of One E-Commerce Corp., appointed George Todaro and Jerry Nadler to its board.
• Kythera Biopharmaceuticals, of Calabasas, Calif., appointed Elisabeth Sandoval chief commercial officer.
• Merz Pharma Group, of Frankfurt, Germany, appointed William D. Humphries North American CEO.
• NPS Pharmaceuticals Inc., of Bedminster, N.J., added Georges Gemayel to it board.
• Onyx Pharmaceuticals Inc., of South San Francisco, named Luigi Costa vice president and head of Europe.
• Permeon Biologics, of Cambridge, Mass., appointed Katherine Bowdish president and chief scientific officer.
• ProMetic Life Sciences Inc., of Laval, Quebec, appointed John Moran to its board.
• pSivida Corp., of Watertown, Mass., named Douglas Godshall to its board.
• S1 Pharmaceuticals Inc., of Jersey City, N.J., appointed Robert Pyke chief medical officer and added Molly Katz to its scientific advisory board.
• SciFluor Life Sciences, of Boston, appointed Mark Duggan vice president, scientific operations; Scott Edwards vice president and general manager, imaging; and Naina Bhasin vice president, business development.
• Sirona Biochem, of Vancouver, British Columbia, appointed Brett Premack scientific consultant.
• SK Biopharmaceuticals Co. Ltd., of Seoul, South Korea, appointed Christopher Gallen CEO.
• Stemline Therapeutics Inc., of New York, appointed Kevin Buchi to its board.